Xuelin Li

197 Ruijin 2nd Road
Shanghai, 200025, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study.

Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study.

Journal: Gut microbes
Published: December 20, 2021

The Intestinal Effect of Atorvastatin: Akkermansia muciniphila and Barrier Function.

The Intestinal Effect of Atorvastatin: Akkermansia muciniphila and Barrier Function.

Journal: Frontiers in microbiology
Published: October 18, 2021

The glucose-lowering effects of α-glucosidase inhibitor require a bile acid signal in mice.

The glucose-lowering effects of α-glucosidase inhibitor require a bile acid signal in mice.

Journal: Diabetologia
Published: September 30, 2019

Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study).

Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study).

Journal: Nature communications
Published: June 12, 2019

Correlation between glucose metabolism and serum steroid hormones in patients with polycystic ovary syndrome.

Correlation between glucose metabolism and serum steroid hormones in patients with polycystic ovary syndrome.

Journal: Clinical endocrinology
Published: May 30, 2019

The impact of shift work on glycemic characteristics assessed by CGM and its association with metabolic indices in non-diabetic subjects.

The impact of shift work on glycemic characteristics assessed by CGM and its association with metabolic indices in non-diabetic subjects.

Journal: Acta diabetologica
Published: March 30, 2019

Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naïve overweight or obese type 2 diabetes patient.

Saxagliptin alters bile acid profiles and yields metabolic benefits in drug-naïve overweight or obese type 2 diabetes patient.

Journal: Journal of diabetes
Published: March 03, 2019

Atorvastatin Targets the Islet Mevalonate Pathway to Dysregulate mTOR Signaling and Reduce β-Cell Functional Mass.

Atorvastatin Targets the Islet Mevalonate Pathway to Dysregulate mTOR Signaling and Reduce β-Cell Functional Mass.

Journal: Diabetes
Published: February 20, 2019
Showing 1-8 of 8

Last Updated: 09/26/2026